摘要
目的探讨异丙托溴铵联合β2受体激动剂治疗儿童哮喘的临床疗效和安全性。方法将哮喘发作患儿随机分为对照组(n=85)和治疗组(n=90),在给予解痉平喘、止咳化痰、应用激素、吸氧和抗感染等常规治疗基础上,对照组给予异丙托溴铵吸入治疗,治疗组给予异丙托溴铵联合沙丁胺醇吸入治疗。监测2组患儿治疗前后肺功能变化情况:用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占肺活量的百分率(FEV1%)、最大呼气峰流速(PEF)。观察并记录患儿肺部哮鸣音、哮喘症状、夜间睡眠和哮喘急性发作次数的改善情况,以及治疗过程中的心率变化和不良反应。结果经治疗,治疗组总有效率95.6%高于对照组的74.1%,2组比较差异有统计学意义(P<0.05);2组患儿的临床症状如咳嗽、憋气、紫绀和呼吸困难均有不同程度的改善,紫绀症状基本消失,双肺哮鸣音减少,睡眠质量提高,肺功能指标FVC、FEV1、FEV1%和PEF水平提高,但治疗组各症状和指标改善情况均优于对照组,2组比较差异有统计学意义(P<0.05)。2组均未观察到明显的不良反应。结论异丙托溴铵联合沙丁胺醇协同作用治疗儿童哮喘具有良好的临床疗效,生物利用度高,患儿的顺应性好。
Objective To explore the clinical effects and safety of ipratropium bromide combined with β receptor agonists in treatment of asthma in children. Methods The patients were divided into control group and therapy group randomly. On the basis of the treatment for asthma, the control group and therapy group were treated with ipratropium bromide, ipratropium bromide combined with salbutamol, respectively. Results After treatment, the clinical symptoms such as cough, suffocated feeling, cyanosis and dififcult breathing were improved on different degree for both of the two groups. The levels of lung function indexes including FVC、FEV 1、FEV 1% and PEF and the total effective rate in therapy group were signiifcantly higher than the control group. Besides, no signiifcant adverse effect was observed. Conclusion The ipratropium bromide combined with salbutamol can be used to relieve asthma in children effectively and synergistically. The bioavailability and the compliance of children are good.
出处
《中国生化药物杂志》
CAS
北大核心
2014年第2期140-142,共3页
Chinese Journal of Biochemical Pharmaceutics
